Home > Long-term reduced risk of CV events with ticagrelor plus aspirin after CABG

Long-term reduced risk of CV events with ticagrelor plus aspirin after CABG

Presented By
Dr Qiang Zhao, Shanghai Jiao Tong University, China

Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 138

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 138

Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 174

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 174

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 175
Conference
AHA 2021
Trial
DACAB-FE
Ticagrelor plus aspirin significantly reduced the risk of cardiovascular events up to 5 years following coronary artery bypass graft (CABG) surgery compared with ticagrelor or aspirin alone. The benefits were mainly associated with a risk reduction of myocardial infarction and ischaemic stroke. “Antiplatelet therapy is guideline-recommended after CABG in patients with acute coronary syndrome,” explained Dr Qiang Zhao (Shanghai Jiao Tong University, China) [1]. “However, there is less evidence on the effect of antiplatelet therapies in patients with chronic coronary syndrome.” The randomised, multicentre, open-label, phase 4 DACAB trial (NCT02201771) showed an improvement in vein graft patency in patients who received ticagrelor (90 mg twice daily) plus aspirin (100 mg once daily; n=168) compared with either one of these therapies alone (n=166 each arm), 1 year after CABG [2]. The current ...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on